其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Sorafenib CAS Registry Number: 284461-73-0 索拉非尼

CAS Name: 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
Additional Names: N-4-(Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar...
Literature References: Multiple kinase inhibitor targeting both RAF kinase and receptor tyrosine kinases that promote angiogensis. Prepn: B. Riedl et al., WO 0041698 (2000 to Bayer); eidem, US 03139605 (2003); D. Bankston et al., Org. Process Res. Dev. 6, 777 (2002). Structure-activity study: U. R. Khire et al., Bioorg. Med. Chem. Lett. 14, 783 (2004). Characterization of kinase inhibition: S. M. Wilhelm et al., Cancer Res. 64, 7099 (2004). Mechanism of action study: D. J. Panka et al., Cancer Res. 66, 1611 (2006). LC determn in serum: S. Afify et al., J. Chromatogr. B 809, 99 (2004). Clinical pharmacokinetics: H. Richly et al., Int. J. Clin. Pharmacol. Ther. 41, 620 (2003). Analysis of clinical safety and efficacy: D. Strumberg et al., Eur. J. Cancer 42, 548 (2006). Clinical evaluation and brief review: H. DeGrendele, Clin. Colorectal Cancer 3, 16-18 (2003). Review of clinical development: B. I. Rini, Expert Opin. Pharmacother. 7, 453-461 (2006).

Pemetrexed CAS Registry Number: 137281-23-3 培美曲塞二钠盐

CAS Name: N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid
Percent Composition: C 56.20%, H 4.95%, N 16.39%, O 22.46%
Literature References: Multitargeted antifolate; inhibits thymidylate synthase as well as other folate dependent enzymes. Prepn: E. C. Taylor et al., EP 432677; idem, US 5344932 (1991, 1994 both to Trustees Princeton Univ.); idem et al., J. Med. Chem. 35, 4450 (1992). Profile of enzyme inhibition: C. Shih et al., Adv. Enzyme Regul. 38, 135 (1998). HPLC determn in plasma: C. L. Hamilton, J. A. Kirkwood, J. Chromatogr. B 654, 297 (1994). Clinical pharmacokinetics in cancer patients: A. C. McDonald et al., Clin. Cancer Res. 4, 605 (1998). Clinical evaluation in colorectal carcinoma: W. John et al., Cancer 88, 1807 (2000); in pancreatic cancer: K. D. Miller et al., Ann. Oncol. 11, 101 (2000).

Cevimeline CAS Registry Number: 107233-08-9 西维美林

CAS Name: (2'R,3R)-rel-2'-Methylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]
Additional Names: (±)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]
Percent Composition: C ...
Literature References: Muscarinic M1 and M3 receptor agonist. Prepn: A. Fisher et al., JP Kokai 61 280497; eidem, US 4855290; (1986, 1989 both to State of Israel). Improved process: K. Hayashi et al., US 5571918 (1996 to Ishihara Sangyo Kaisha). Sialogogic effect in animals: H. Masunaga et al., Eur. J. Pharmacol. 339, 1 (1997). General pharmacology: H. Arisawa et al., Arzneim.-Forsch. 52, 14, 81 (2002). Clinical experience in Sjögren's syndrome dry eye: M. Ono et al., Am. J. Ophthalmol. 138, 6 (2004); in dry mouth: K. Suzuki et al., Pharmacology 74, 100 (2005). Review of clinical pharmacokinetics and efficacy in Sjögren's syndrome: H. Yasuda, H. Niki, Clin. Drug Invest. 22, 67-73 (2002).

Solifenacin CAS Registry Number: 242478-37-1 索利那新

CAS Name: (1S)-3,4-Dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester
Additional Names: (1S,3'R)-3'quinuclidinyl-1-phenyl-1,2,3,4-tetrahydro-2-isoquinolin...
Literature References: Muscarinic M3 receptor antagoinst. Prepn: M. Takeuchi et al., WO 9620194; eidem, US 6017927 (1996, 2000 both to Yamanouchi). Receptor binding studies: K. Ikeda et al., Arch. Pharmacol. 366, 97 (2002); selectivity profile: A. Ohtake et al., Eur. J. Pharmacol. 492, 243 (2004). Clinical study in overactive bladder: C. R. Chapple et al., Br. J. Urol. 93, 303 (2004); F. Habb et al., Eur. Urol. 47, 376 (2005). Clinical comparison with tolterodine: C. R. Chapple et al., ibid. 48, 464 (2005). Review of efficacy and tolerability studies: S. Brunton, L. Kuritzky, Curr. Med. Res. Opin. 21, 71-80 (2005); of clinical development: C. K. Payne, Drugs 66, 175-190 (2006).

Oxybutynin CAS Registry Number: 5633-20-5 奥昔布宁

CAS Name: a-Cyclohexyl-a-hydroxybenzeneacetic acid 4-(diethylamino)-2-butynyl ester
Additional Names: a-phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester; 4-diethylamino-2-butynyl...
Literature References: Muscarinic receptor antagonist. Prepn: GB 940540 (1963 to Mead Johnson). Physico-chemical properties: E. Miyamoto et al., Analyst 119, 1489 (1994). GC-MS determn in plasma: K. S. Patrick et al., J. Chromatogr. 487, 91 (1989). Toxicity: E. I. Goldenthal, Toxicol. Appl. Pharmacol. 18, 185 (1971). Review of pharmacodynamics and therapeutic use: Y. E. Yarker et al., Drugs Aging 6, 243-262 (1995).

Tolterodine CAS Registry Number: 124937-51-5 托特罗定

CAS Name: 2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol
Additional Names: (+)-(R)-2-[a-[2-(diisopropylamino)ethyl]benzyl]-p-cresol; (+)-N,N-diisopropyl-3-(2-hydroxy-5-methy...
Literature References: Muscarinic receptor antagonist. Prepn: N. A. Jönsson et al., EP 325571 (1989 to KabiVitrum); eidem, US 5382600 (1995 to Pharmacia). Asymmetric total synthesis: C. Hedberg, P. G. Andersson, Adv. Synth. Catal. 347, 662 (2005). Pharmacology: L. Nilvebrant et al., Life Sci. 60, 1129 (1997). Receptor binding study: idem et al., Eur. J. Pharmacol. 327, 195 (1997). GC-MS determn in biological fluids: L. Palmér et al., J. Pharm. Biomed. Anal. 16, 155 (1997). Clinical pharmacokinetics: N. Brynne et al., Int. J. Clin. Pharmacol. Ther. 35, 287 (1997). Review of clinical trials: R. A. Appell, Urology 50, Suppl. 6A, 90-96 (1997); of use in overactive bladder: E. S. Rovner, Expert Opin. Pharmacother. 6, 653-666 (2005).

Tiotropium Bromide CAS Registry Number: 136310-93-5 噻托溴铵

CAS Name: (1a,2b,4b,5a,7b)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide
Additional Names: 6b,7b-epoxy-3b-hydroxy-8-methyl-1aH,5aH-tropanium b...
Literature References: Muscarinic receptor antagonist. Prepn: R. Banholzer et al., EP 418716; eidem, US 5610163 (1991, 1997 both to Boehringer Ingelheim). Pharmacology: T. Takahashi et al., Am. J. Respir. Crit. Care Med. 150, 1640 (1994). Binding study: E.-B. Haddad et al., Mol. Pharmacol. 45, 899 (1994). Comparative clinical trial with salmeterol, q.v., in chronic obstructive pulmonary disease (COPD): J. F. Donohue et al., Chest 122, 47 (2002).

Exaltolide® (Firmenich) CAS Registry Number: 106-02-5 环十五内酯

CAS Name: Oxacyclohexadecan-2-one
Additional Names: 15-hydroxypentadecanoic acid e-lactone
Percent Composition: C 74.95%, H 11.74%, O 13.31%
Literature References: Musk compd responsible for the pleasant odor of angelica root oil. Synthesis: Ruzicka, Stoll, Helv. Chim. Acta 11, 1159 (1928); Carnduff et al., Chem. Ind. (London) 1960, 559; Dhenkne et al., J. Chem. Soc. 1962, 2348; Mathur, Bhattacharya, ibid. 1963, 3505; Becker, Ohloff, Helv. Chim. Acta 54, 2889 (1971). Alternate syntheses: T. Mukaiyama et al., Chem. Lett. 1977, 441; K. Narasaka et al., ibid. 763; W. H. Kruizinga, R. M. Kellogg, Chem. Commun. 1979, 286.

Sinalbin CAS Registry Number: 20196-67-2 [2-[3-(4-羟基-3,5-二甲氧基苯基)丙烯氧]乙基,三甲基铵,盐与1-硫代-β-D-葡萄糖蓄糖1-[4-羟基-N-(磺氧基)苯乙酰胺](1:1)

Additional Names: Sinapine glucosinalbate
Percent Composition: C 49.04%, H 5.76%, N 3.81%, O 32.66%, S 8.73%
Literature References: Mustard oil glucoside from white or yellow mustard (Sinapis alba L., Cruciferae): Gadamer, Arch. Pharm. 235, 38, 83, 570 (1897); Viehoever, Nelson, J. Assoc. Off. Agric. Chem. 21, 488 (1938); Am. J. Pharm. 110, 411 (1938). Structure: Schulz, Gmelin, Z. Naturforsch. 7b, 500 (1952); Ettlinger, Lundeen, J. Am. Chem. Soc. 78, 4172 (1956).

Doramectin CAS Registry Number: 117704-25-3 多拉菌素

CAS Name: 25-Cyclohexyl-5-O-demethyl-25-de(1-methylpropyl)avermectin A1a
Additional Names: 25-cyclohexylavermectin B1Trademarks: Dectomax (Pfizer)
Percent Composition: C 66.79%, H 8.30%, O 2...
Literature References: Mutational biosynthetic antiparasitic antibiotic structurally related to the avermectins, q.v. Isoln: S. P. Gibson et al., EP 214731; eidem, US 5089480 (1987, 1992 both to Pfizer). Mutational biosynthesis: C. J. Dutton et al., J. Antibiot. 44, 357 (1991). Pharmacokinetics and efficacy in cattle: Vet. Parasitol. 49, 1-119 (1993). Clinical evaluation as prophylactic in canine spirocercosis: E. Lavy et al., Res. Vet. Sci. 75, 217 (2003).